UY30280A1 - Esteres derivados del acido 4-(-2-oxo-1,2,4,5-tetrahidro-1, 3-benzodiacepin-3-il)-piperidin-1-carboxilico, sus polimorfos, sus solvatos y sus hidratos, composiciones, preparacion y aplicaciones. - Google Patents

Esteres derivados del acido 4-(-2-oxo-1,2,4,5-tetrahidro-1, 3-benzodiacepin-3-il)-piperidin-1-carboxilico, sus polimorfos, sus solvatos y sus hidratos, composiciones, preparacion y aplicaciones.

Info

Publication number
UY30280A1
UY30280A1 UY30280A UY30280A UY30280A1 UY 30280 A1 UY30280 A1 UY 30280A1 UY 30280 A UY30280 A UY 30280A UY 30280 A UY30280 A UY 30280A UY 30280 A1 UY30280 A1 UY 30280A1
Authority
UY
Uruguay
Prior art keywords
acid
solvates
benzodiacepin
hydrats
carboxilico
Prior art date
Application number
UY30280A
Other languages
English (en)
Inventor
Anreas Zopf
Sonja Sproll
Gunther Huchler
Uwe Ries
Dr Ulrike Werthmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY30280A1 publication Critical patent/UY30280A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invencion se refiere a los nuevos compuestos cristalinos A de la formula general I en la que A1, A2, A3, X, Y1, Y2 e Y3 están definidos como en la reivindicacion 1, y que se presentan en forma de sus sales con ácidos, fisiologicamente tolerables, seleccionándose los ácidos a partir del grupo B constituido por ácido clorhídrico, ácido bromhídrico, ácido sulfurico, ácido forforico, ácido bencenosulfonico, ácido p-toluenosulfonico, ácido maleico, ácido succínico, ácido fumário, ácido D-(-)-tartárico, ácido L-(+)-tartárico, ácido naftalin-2-sulfonico y ácido naftalin-1,5-disulfonico, así como a los polimorfos, a los correpondientes solvatos e hidratos.
UY30280A 2006-04-13 2007-04-12 Esteres derivados del acido 4-(-2-oxo-1,2,4,5-tetrahidro-1, 3-benzodiacepin-3-il)-piperidin-1-carboxilico, sus polimorfos, sus solvatos y sus hidratos, composiciones, preparacion y aplicaciones. UY30280A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006017827A DE102006017827A1 (de) 2006-04-13 2006-04-13 Neue kristalline Verbindungen

Publications (1)

Publication Number Publication Date
UY30280A1 true UY30280A1 (es) 2007-11-30

Family

ID=38514672

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30280A UY30280A1 (es) 2006-04-13 2007-04-12 Esteres derivados del acido 4-(-2-oxo-1,2,4,5-tetrahidro-1, 3-benzodiacepin-3-il)-piperidin-1-carboxilico, sus polimorfos, sus solvatos y sus hidratos, composiciones, preparacion y aplicaciones.

Country Status (20)

Country Link
US (1) US7638625B2 (es)
EP (1) EP2010513A2 (es)
JP (1) JP2009533387A (es)
KR (1) KR20090007428A (es)
CN (1) CN101421263A (es)
AR (1) AR060442A1 (es)
AU (1) AU2007239505A1 (es)
BR (1) BRPI0710151A2 (es)
CA (1) CA2648140A1 (es)
CO (1) CO6140057A2 (es)
DE (1) DE102006017827A1 (es)
EA (1) EA200802049A1 (es)
EC (1) ECSP088737A (es)
MX (1) MX2008013158A (es)
NO (1) NO20083709L (es)
PE (1) PE20080735A1 (es)
TW (1) TW200808767A (es)
UY (1) UY30280A1 (es)
WO (1) WO2007118819A2 (es)
ZA (1) ZA200806859B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2008015562A (es) * 2006-06-08 2008-12-17 Boehringer Ingelheim Int Tratamiento de trastornos gastrointestinales con antagonistas de cgrp.
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04375B1 (et) 1996-09-10 2004-10-15 Dr. Karl Thomae Gmbh Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP2010513A2 (de) 2009-01-07
JP2009533387A (ja) 2009-09-17
DE102006017827A1 (de) 2007-10-18
ECSP088737A (es) 2008-10-31
EA200802049A1 (ru) 2009-04-28
US7638625B2 (en) 2009-12-29
AU2007239505A1 (en) 2007-10-25
CA2648140A1 (en) 2007-10-25
WO2007118819A2 (de) 2007-10-25
NO20083709L (no) 2008-10-31
MX2008013158A (es) 2008-10-22
BRPI0710151A2 (pt) 2011-08-02
ZA200806859B (en) 2009-08-26
US20080086003A1 (en) 2008-04-10
KR20090007428A (ko) 2009-01-16
TW200808767A (en) 2008-02-16
CO6140057A2 (es) 2010-03-19
CN101421263A (zh) 2009-04-29
PE20080735A1 (es) 2008-07-25
WO2007118819A3 (de) 2008-05-29
AR060442A1 (es) 2008-06-18

Similar Documents

Publication Publication Date Title
CY1123658T1 (el) Μεθοδος για τη δημιουργια χημικων ενωσεων κινολονης
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
BRPI0813284A8 (pt) Processo para a preparação de um composto da fórmula (i) e composto
EA201200537A1 (ru) Способ получения глюкопиранозил-замещенных производных бензилбензола
BRPI0812625A2 (pt) processo para preparar um sal de cis-atracúrio
AR075227A1 (es) Procedimiento de sintesis de ivabradina y sus sales de adicion de acidos farmaceuticamente aceptables.
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
MY152281A (en) 4-pyrimidinesulfamide derivative
UY32077A (es) Inhibidores de quinasa tipo polo
SG10201407913UA (en) Crystalline freebase forms of a biphenyl compound
BR112012017448A2 (pt) método para a preparação de sais de ácido metanossulfônico de tetrazol, e novo composto empregado no mesmo
UY30280A1 (es) Esteres derivados del acido 4-(-2-oxo-1,2,4,5-tetrahidro-1, 3-benzodiacepin-3-il)-piperidin-1-carboxilico, sus polimorfos, sus solvatos y sus hidratos, composiciones, preparacion y aplicaciones.
CY1116974T1 (el) Παραγωγα 5-υδροξυπυριμιδινο-4-καρβοξαμιδιου
CL2010001639A1 (es) Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina.
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
CY1114493T1 (el) Διαδικασια για την παρασκευη μιας ενωσης χρησιμης ως αναστολεα της tafia
AR078179A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
CU20120065A7 (es) Derivado de 4-[etil(dimetil)amonio] butanoato para el tratamiento de enfermedades cardiovasculares y sus métodos de obtención
AR085344A1 (es) Proceso de sintesis de ivabradina e intermediarios de dicha sintesis
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
RS54279B1 (en) SYNTHESIS PROCEDURE AND CRYSTAL FORM 4- {3- [CIS-HEXAHIDROCYCLOPENT [C] PIROL-2 (1H) -IL] PROPOXY} BENZAMIDE HYDROCHLORIDE, ASSOCIATED FREE BASES AND PHARMACEUTICAL MIXTURES CONTAINING THESE

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170606